Related Experiment Video
Updated: Jun 4, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Potential treatment options and future research to increase hepatitis C virus treatment response rate
Veronica Tencate1, Bruno Sainz, Scott J Cotler
1Department of Medicine, Section of Hepatology, University of Illinois at Chicago, Chicago, IL, USA.
Insights
Hepatitis C virus (HCV) infection persists in most cases, leading to severe liver disease. New therapies targeting the viral life cycle offer improved treatment options for this global health concern.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) affects over 170 million globally, causing significant liver disease.
- Chronic HCV infection can lead to fibrosis, cirrhosis, steatosis, insulin resistance, and hepatocellular carcinoma.
- Current standard care (pegylated interferon α + ribavirin) has limited efficacy and toxicity.
Purpose of the Study:
- To review limitations of current HCV therapy.
- To evaluate emerging HCV treatment strategies.
- To discuss how understanding the HCV life cycle aids antiviral development.
Main Methods:
- Literature review of current and emerging HCV therapies.
- Analysis of research on HCV viral life cycle.
- Evaluation of treatment outcomes for existing and novel antivirals.
Main Results:
- Current standard care is effective in a subset of patients.
- New HCV antivirals demonstrate improved efficacy and reduced toxicity.
- Elucidating the HCV life cycle is crucial for developing targeted therapeutics.
Conclusions:
- Development of effective, less toxic HCV antivirals is a priority.
- Novel HCV therapeutics promise better treatment response rates.
- Improved treatments are needed for both pre- and post-liver transplantation patients.
Abstract:
Hepatitis C virus (HCV) is a liver-tropic blood-borne pathogen that affects more than 170 million people worldwide. Although acute infections are usually asymptomatic, up to 90% of HCV infections persist with the possibility of long-term consequences such as liver fibrosis, cirrhosis, steatosis, insulin resistance, or hepatocellular carcinoma. As such, HCV-associated liver disease is a major public health concern. Although the currently available standard of care therapy of pegylated interferon α plus ribavirin successfully treats infection in a subset of patients, the development of more effective, less toxic HCV antivirals is a health care imperative. This review not only discusses the limitations of the current HCV standard of care but also evaluates upcoming HCV treatment options and how current research elucidating the viral life cycle is facilitating the development of HCV-specific therapeutics that promise to greatly improve treatment response rates both before and after liver transplantation.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Microorganisms in Medicine and Therapeutics
Pharmacogenomics: Identification of New Drug Targets
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test